Form 8-K - Current report:
SEC Accession No. 0001641172-25-002514
Filing Date
2025-04-03
Accepted
2025-04-03 08:55:26
Documents
16
Period of Report
2025-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 46571
2 ex10-1.htm EX-10.1 278970
3 ex10-2.htm EX-10.2 100422
4 ex10-3.htm EX-10.3 92532
  Complete submission text file 0001641172-25-002514.txt   797945

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE erna-20250331.xsd EX-101.SCH 3015
6 XBRL LABEL FILE erna-20250331_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE erna-20250331_pre.xml EX-101.PRE 24165
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3701
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 25807635
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)